CANLI
Yükleniyor Veriler getiriliyor…
SCI-Expanded Özgün Makale Scopus
The relationship between serum clozapine concentrations and hematological parameters by a validated mass spectrometric method
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS 2020 Cilt 180
Scopus Eşleşmesi Bulundu
6
Atıf
180
Cilt
Scopus Yazarları: Abdullah Sivrikaya, Oguzhan Tok, Ali Ünlü, Karam Mazin Kamil Gharab, Duygu Eryavuz Onmaz, Sedat Abusoglu, Memduha Aydin, Gulsum Abusoglu
Özet
Objective: Clozapine is one of the most effective drugs for resistant schizophrenia, but its severe metabolic and hematological side effects limit the use of clozapine. It has been reported that clozapine blood concentrations should be maintained between 350−600 ng/mL. Our aim was to develop a determination method for clozapine and its main metabolites norclozapine and clozapine-N-oxide, to perform validation studies and to investigate the change of various biochemical parameters in patients using clozapine. Methods: A liquid chromatography-tandem mass spectrometry (LC–MS/MS) method was developed and validated for clozapine measurement. Thus, blood samples were collected from 38 patients with schizophrenia and 32 healthy volunteers. Biochemical and hematological parameters were measured by Beckman-Coulter AU 5800 (Beckman Coulter, Brea, USA) and Beckman Coulter LH 780 analyzer (Beckman Coulter, Miami, FL, USA), respectively. Hormone levels were analyzed using Cobas 6000 analyzer (Roche Diagnostics, Germany). Results: The LC[sbnd]MS/MS method was linear between 1.22−2500 ng/mL (r2 = 0.9971) for clozapine. The retention times of clozapine, norclozapine and clozapine-N-oxide were 0.92, 0.89 and 0.95, respectively. Blood glucose (GLU) (p = 0.025), low density lipoprotein (LDL-cholesterol) (p = 0.015), triglyseride (TG) (p = 0.042) and total cholesterol (TC) (p = 0.024) levels were higher; hemoglobin (HGB) (0.015), mean corpuscular hemoglobin (MCH) (0.036), red blood cell count (RBC) (0.020), neutrophil (NEU) (0.034), and platelet (PLT) (P = 0.005) levels were lower in the clozapine group. Conclusions: This LC–MS/MS method was rapid, simple, cost-effective and suitable for the routine clozapine monitoring. Furthermore, norclozapine and clozapine-N-oxide were also determined. Monitoring of metabolic and hematological parameters with clozapine levels is very important. However, the limitations of the study were that the method was not validated for norclozapine and clozapine-N-oxide, so the validation parameters were not evaluated for these two metabolites.
Anahtar Kelimeler (Scopus)
Therapeutic drug monitoring Clozapine Side effects Tandem mass spectrometry
Scimago Dergi Bilgisi Otomatik ISSN Eşleştirmesi 2020 yılı verileri
Journal of Pharmaceutical and Biomedical Analysis
Q1
SJR Quartile
0,777
SJR Skoru
154
H-Index
Kategoriler: Pharmaceutical Science (Q1) · Analytical Chemistry (Q2) · Clinical Biochemistry (Q2) · Drug Discovery (Q2) · Spectroscopy (Q2)
Alanlar: Biochemistry, Genetics and Molecular Biology · Chemistry · Pharmacology, Toxicology and Pharmaceutics
Ülke: Netherlands · Elsevier B.V.
Bu bilgiler makale yılına göre Scimago veritabanından ISSN eşleştirmesiyle otomatik getirilmektedir. Dergi sıralama verileri Scimago'nun ilgili yılı baz alınmaktadır.

Anahtar Kelimeler

Therapeutic drug monitoring Clozapine Side effects Tandem mass spectrometry

Makale Bilgileri

Dergi JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
ISSN 0731-7085
Yıl 2020 / 2. ay
Cilt / Sayı 180
Sayfalar 1 – 7
Makale Türü Özgün Makale
Hakemlik Hakemli
Endeks SCI-Expanded
Yayın Dili İngilizce
Kapsam Uluslararası
Toplam Yazar 8 kişi
Erişim Türü Elektronik
Erişim Linki Makaleye Git
Alan Sağlık Bilimleri Temel Alanı- Tıbbi Biyokimya

YÖKSİS Yazar Kaydı

Yazar Adı Kamil Gharab Karam,Onmaz Duygu Eryavuz,Abusoglu Sedat,AYDIN MEMDUHA,SİVRİKAYA ABDULLAH,Tok Oğuzhan,Abusoglu Gulsum,ÜNLÜ ALİ
YÖKSİS ID 4447428